DGEN Projected Dividend Yield

Deltagen Inc ( OTCBB : DGEN )

Co. is engaged in using in vivo derived mammalian gene function information to define the function and disease relevance of mammalian genes for the purposes of discovering and validating novel drug targets. Co.'s information platform serves Co. pharmaceutical partners and customers in their efforts to discover potential new drug therapies as well as Co.'s internal drug discovery efforts. Co.'s platform product, DeltaBase®, provides a database of in vivo mammalian gene function information on target genes selected for their disease relevance. Co. deletes, or ¿knocks out¿, these genes in mice and then utilizes an integrated analysis program to assess the function and potential pharmaceutical relevance of these genes and the proteins these genes encode.

28 YEAR PERFORMANCE RESULTS